Skip to main content
Figure 3 | Australia and New Zealand Health Policy

Figure 3

From: The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines

Figure 3

Monthly expenditure on anti-rheumatic drugs under the PBS and RPBS, August 2003–July 2005. Note: Expenditure on DMARDs was obtained from the Drug Utilization Sub-Committee database. DMARDs included: methotrexate, azathioprine, cyclophosphamide, cyclosporin, hydroxychloroquine, penicillamine, sulfasalazine, gold preparations (sodium aurothiomalate and auranofin), and leflunomide.

Back to article page

Australia and New Zealand Health Policy

ISSN: 1743-8462